A Phase 1b/2 Open-label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)

Go Back to All Clinical Trials

A Phase 1b/2 Open-label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Metastatic Breast Cancer
Age: Between 6 Year(s) - 22 Year(s)
Gender: Female

Other Inclusion Criteria:
1. Histopathologically or cytologically confirmed ER+
2. Histopathologically or cytologically confirmed HER2-
3. Histopathologically or cytologically confirmed breast cancer

You may not be eligible for this study if the following are true:

1. Active or newly diagnosed CNS metastases, including meningeal carcinomatosis
2. Prior chemotherapy or elacestrant in the advanced/metastatic setting
3. A concurrent malignancy or history of invasive malignancy within 3 years of enrollment, with the exception of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix that has completed curative therapy

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies